NCT00457145View on ClinicalTrials.gov

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 27, 2007

Study Completion Date

October 24, 2007

Conditions
Telangiectasia
Interventions
DRUG

Ranibizumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Eye Institute (NEI)

NIH

NCT00457145 - Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation | Biotech Hunter | Biotech Hunter